| Bioactivity | MTI013 is a selective SARS-CoV-2 nsp14 Mtase inhibitor (IC50: 2.98 μM) and an antiviral agent (IC50: 10.33 μM in HCoV-229E-infected Huh7 cells). MTI013 also shows a synergistic antiviral effect with the RdRp inhibitor SHEN26 (HY-155488)[1]. |
| Target | IC50: 2.98 μM (nsp14 Mtase) |
| Formula | C24H24N6O4S |
| Molar Mass | 492.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen Q, et al. Identification of adenosine analogues as nsp14 N7‑methyltransferase inhibitors for treating coronaviruses infection. Bioorg Chem. 2024 Oct 18;153:107894. |